360Dx

Asuragen Myotonic Dystrophy 1 Dx Kit Receives CE Mark

Dec 04, 2018

NEW YORK (GenomeWeb) — Asuragen said today that it has received CE marking for its AmplideX DM1 Dx kit for use in the diagnosis of myotonic dystrophy type I (DM1).

DM1, also known as Steinert's disease, is an inherited form of muscular dystrophy characterized by a repeat expansion of 50 CTG trinucleotides or greater in the DMPK gene. According to Asuragen, disease severity positively correlated to the number of repeats, which can extend beyond 1,000.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Asuragen Myotonic Dystrophy 1 Dx Kit Receives CE Mark

To read the full story....

Breaking News

T2 Biosystems Q2 Revenues Up 41 Percent, Beat Estimates

FDA Grants Emergency Use Authorization for George Washington University Coronavirus PCR Test

Adaptive Biotechnologies Q2 Revenues Fall 5 Percent, Beat Analyst Estimates

Castle Biosciences Q2 Revenues Up 18 Percent

HTG Molecular Diagnostics, Qiagen Ink CDx Commercialization, Distribution Agreement

Helix Gets FDA Emergency Use Authorization for NGS-Based COVID-19 Test

Featured White Papers

COVID-19 Wastewater-Based Epidemiology: Methods and Insights for SARS-CoV-2 Community Surveillance

Navigating the FDA's EUA Process for Diagnostics in the Present and Future: A Stakeholder Panel Discussion

What's Popular?

FDA Grants Emergency Use Authorization for George Washington University Coronavirus PCR Test

Sysmex America to Distribute Siemens Urine Analyzer in North America

Guardant Health Colorectal Cancer Early-Detection Test Progresses Despite Pandemic Challenges

Illumina Sees Expanding Sequencing Market in COVID-19 Response, Despite Short-Term Woes

Adaptive Biotechnologies Q2 Revenues Fall 5 Percent, Beat Analyst Estimates

Sponsorships